胰岛素样生长因子Ⅰ及胰岛素与胎儿宫内发育迟缓发病的关系

目的 探讨胰岛素样生长因子１（ＩＧＦ－Ｉ）及胰岛素与胎儿宫内发育迟缓（ＩＵＧＲ）发病的关系。方法 应用放射免疫分析法和酶联免疫吸附试验,分别测定１７例ＩＵＧＲ患儿,孕妇（ＩＵＧＲ组）血清及羊水中Ｉｎｓ和ＩＧＦ－Ｉ水平,同期住院的正常晚期妊娠妇女３８例（正常妊娠组）作为对照。     

表皮生长因子及其受体与胎儿出生体重的关系

目的探讨表皮生长因子（ＥＧＦ）及其受体与胎儿出生体重的关系。方法采用酶联免疫吸附测定法对正常非孕妇女１５例（对照组）、足月正常体重儿４０例（正常体重儿组）、ＩＵＧＲ儿４０例（ＩＵＧＲ儿组）、巨大儿２５例（巨大儿组）的母血清、脐血清及羊水中ＥＧＦ浓度进行测定,同时采用免疫组化方法对以上各组胎盘及胎膜上ＥＧＦ受体（ＥＧＦＲ）进行测定。结果各组母血、脐血及羊水中ＥＧＦ浓度明显高于对照组（Ｐ＜００５）。ＩＵＧＲ儿组母血、脐血及羊水中ＥＧＦ浓度低于正常体重儿组,差异有显著性。巨大儿组母血、脐血及羊水中ＥＧＦ浓度与正常体重儿组比较,差异无显著性。在ＩＵＧＲ儿组胎盘及胎膜上ＥＧＦＲ表达明显低于正常体重儿组（Ｐ＜０．０１）,巨大儿组胎盘上ＥＧＦＲ表达高于正常体重儿组。结论ＥＧＦ及其受体与ＩＵＧＲ的发生有关,在妊娠后期测定母血及羊水中ＥＧＦ浓度,对评价胎儿的生长发育具有重要意义。     

胎儿宫内发育迟缓时孕妇及胎儿心钠素的变化及意义

目的 :探讨胎儿宫内发育迟缓的孕妇血清、脐血和羊水中心钠素水平的变化。方法 :采用放射免疫法测定正常足月妊娠 6 2例 (正常组 )和足月妊娠 IUGR38例 (IU GR组 )孕妇血清、脐血和羊水中心钠素的水平。结果 :IU GR组孕妇脐血中心钠素水平显著下降 (P<0 .0 5 ) ,血清和羊水中心钠素水平与正常组比较无显著差异 (P>0 .0 5 )。结论 :心钠素分泌不足可能是 IUGR发病原因之一 ,它对维持胎儿内环境平衡产生重要作用     

胎儿宫内发育迟缓时胎盘病理改变与孕妇血及脐血中一氧化氮 …

目的 了解胎儿宫内发育迟缓（ＩＵＧＲ）时胎病理改变与母血及脐血中一氧化氮（ＮＯ）水平的关系。方法 对１９９７年１１月￣１９９８年１０月３８例妊娠合并胎儿宫内发育迟缓（ＩＵＧＲ组）及３０例正常３０例正常孕妇（对照组）分娩后的胎盘及胎儿附属物进行分析。     

表皮生长因子与胎儿宫内发育迟缓关系的研究

探讨表皮生长因子与胎儿宫内发育迟缓的关系。方法用放射免疫分析,测定８６例妊娠晚期妇女血清,羊水和脐静脉血ＥＧＦ浓度;根据新生儿出生体重,将研究对象分成对照组５４例,大于胎龄儿组１８例和ＩＵＧＲ组１４例。对照组中有１１例同时测定脐动脉血清ＥＧＦ浓度,比较各组间羊水和孕妇,脐血清ＥＧＦ水平及脐动,静脉血清间ＥＧＦ水平的差异。     

胎儿宫内发育迟缓时胎盘病理改变与孕妇血及脐血中一氧化氮水平的关系

目的了解胎儿宫内发育迟缓（ＩＵＧＲ）时胎盘病理改变与母血及脐血中一氧化氮（ＮＯ）水平的关系。方法对１９９７年１１月～１９９８年１０月３８例妊娠合并胎儿宫内发育迟缓（ＩＵＧＲ组）及３０例正常孕妇（对照组）分娩后的胎盘及胎儿附属物进行分析。用隔还原显色法测定母血及脐血ＮＯ水平。结果ＩＵＧＲ组中２６例有胎盘、脐带病理改变（６８．４２％）。主要表现为绒毛发育迟缓及绒毛炎;对照组中５例有胎盘病理改变（１６．６７％）,两组比较差异有极显著性（Ｐ＜０．０１）;ＩＵＧＲ组中母血及脐血ＮＯ水平均低于对照组（Ｐ＜０．０５,Ｐ＜０．０１）;ＩＵＧＲ组中２６例胎盘病理改变明显,其母血及脐血ＮＯ水平低于胎盘无明显病理改变者（Ｐ＜０．０５,Ｐ＜０．０５）;两组脐血ＮＯ水平均高于母血ＮＯ水平（Ｐ＜０．０１,Ｐ＜０．０５）,两组脐血与母血ＮＯ水平均有相关性（ｒ＝０．５４７５,ｒ＝０．８５０６）;脐血ＮＯ水平与新生儿体重在ＩＵＧＲ组未发现明显相关性（ｒ＝０．２８３８）。结论ＩＵＧＲ时,胎盘发生明显病理变化,导致母血及脐血中ＮＯ的水平降低。     

胎儿生长迟缓孕妇淋巴细胞姐妹染色单体的互换频率

目的：了解胎儿生长迟缓（ＩＵＧＲ）孕妇外周血及新生儿脐血姐妹染色单体互换（ＳＣＥ）频率的变化。方法：应用姐妹染色单体互换技术，对１４例单纯性ＩＵＧＲ孕妇（ＩＵＧＲ组）及９０例正常孕妇（对照组）的外周血及其所分娩新生儿脐血ＳＣＥ频率进行测定。结果：ＩＵＧＲ组外周血及脐血ＳＣＥ频率分别为１０．５３±２．６９，７．２５±１．３４；对照组外周血及脐血ＳＣＥ频率分别为７．５８±０．３２，５．０５±０．２９；两组比较，差异有极显著性（Ｐ均＜０．０１）。ＩＵＧＲ组外周血及脐血ＳＣＥ频率全部异常。结论：ＩＵＧＲ与遗传物质损伤有关，ＳＣＥ频率有可能作为一项诊断ＩＵＧＲ的新指标。     

IUGR脐血中表皮生长因子水平的研究

目的：从内分泌因素的角度对胎儿生长发育及其异常进行研究，以探讨ＩＵＧＲ与脐血中表皮生长因子（ＥＧＦ）水平的关系。方法：选择伴有ＩＵＧＲ的孕妇２２例及正常孕妇３８例，于分娩时抽取脐血，用放射免疫测定法（ＲＩＡ）测定ＥＧＦ水平，同时测定胎儿体重与胎盘重量，比较两组的差异。结果：正常体重儿（３４０９．１±２８４．７９ｇ）组的脐血ＥＧＦ水平（６２４．６４±７３．９０μｇ／Ｌ）明显高于低体重儿（２４０３．３±２７７．４１ｇ）组（２１７．９０±５４．５２μｇ／Ｌ）（Ｐ＜０．０５）；ＩＵＧＲ组胎盘重量３５４．３±９２．６４ｇ亦明显低于正常组的５４２．１±７８．３２ｇ（Ｐ＜０．０１）。结论：脐血中低ＥＧＦ水平是ＩＵＧＲ的相关因素之一，对妊娠过程中ＥＧＦ的作用及其机制进行研究有助于探讨ＩＵＧＲ病因及临床治疗。     

PGE2与胎儿胎盘循环

目的　探讨前列腺素Ｅ２（ＰＧＥ２ ）对正常妊娠及妊高征孕妇胎儿胎盘循环的调节作用。　方法　在５０例足月正常孕妇（对照组）及３７例妊高征合并ＩＵＧＲ孕妇（妊高征组）中,利用共焦点激光扫描显微镜测定了ＰＧＥ２对人脐静脉内皮细胞（ＨＵＶＥＣ）内游离钙离子（Ｃａ２＋ ）ｉ动态变化的影响,同时用放免法测定了其脐静脉血中ＰＧＥ２浓度。　结果　ＰＧＥ２ 使两组ＨＵＶＥＣ中（Ｃａ２＋ ）ｉ上升, 脐血中ＰＧＥ２ 值在妊高征组为５．４±０．６ ｐｇ／ｍ ｌ与对照组的１５．３±１．２ ｐｇ／ｍ ｌ相比,显示有意义的低值（Ｐ＜０．０５）。　结论　ＰＧＥ２ 可能为胎儿胎盘循环的血管扩张因子;妊高征组脐血中ＰＧＥ２ 浓度降低使胎儿胎盘血流阻力增加可能影响胎儿生长发育     

孕妇血清表皮生长因子在判断胎儿成熟度中的价值

目的了解正常孕妇在妊娠各期血清中表皮生长因子（ＥＧＦ）及孕激素（Ｐ）,与羊水中ＥＧＦ、Ｐ、淀粉酶（Ａｍｓ）、肌酐（Ｃｒ）、间接胆红素（ＴＢ）的浓度变化在判断胎儿成熟度中的价值。方法用放射免疫法测定正常孕妇１８１例（早孕３５例,中孕６９例,晚孕７７例）血清及其中８７例孕妇（中孕４４例,晚孕４３例）羊水中的ＥＧＦ、Ｐ浓度变化;用生化分析仪测定此８７例孕妇羊水中Ａｍｓ、Ｃｒ、ＴＢ浓度变化。同时还对其中２３例足月分娩的新生儿的脐静脉、脐动脉血清中ＥＧＦ及Ｐ的浓度进行测定。结果孕妇血清中ＥＧＦ和Ｐ的浓度均随孕周增长而增加。羊水中ＥＧＦ浓度与羊水中Ａｍｓ、Ｃｒ浓度呈正相关。孕３２周以后,当ＥＧＦ≥４．５μｇ／Ｌ时,胎儿成熟率为７０．５９％。结论妊娠期孕妇血清中ＥＧＦ的浓度变化可用于判断胎儿成熟度     

宫内发育迟缓早产儿胰岛素 生长激素及皮质醇的变化和发病关系研究

摘要】目的探讨胰岛素(Ins)、生长激素(GH)、皮质醇(Cor)与早产儿宫内发育迟缓 (IUGR)的关系。方法采用放射免疫分析法检测40例IUGR早产儿和45例适于胎龄早产儿(对照组)母血、脐血和生后7日龄血清中的Ins、GH、Cor含 量，并进行分析比较。结果Ins在IUGR组脐血、生后7日龄血清中的含量明显低于对照组(P<0.05)。GH、Cor在母血中含量明显低于对照组 (P<0.05)。而脐血、生后7日龄血清中Cor含量在IUGR高于对照组，但二组比较差异无显著性(P>0.05)。结论早产儿IUGR与Ins、GH、Cor等内分 泌激素有关，它们通过调节代谢而影响胎儿宫内的生长发育，发挥着较重要的作用。     

Effects of maternal oral salbutamol therapy on neonatal endocrine status at birth

Cord blood concentrations of insulin, growth hormone (GH), triiodothyronine (T3), thyroxine (T4), and thyroid-stimulating hormone (TSH) from 20 patients treated with oral salbutamol were compared with those of 18 matched patients who had not received any betamimetic agents. No significant difference was found in circulating insulin, T3, T4, and TSH between both groups. However, GH levels were significantly higher in the treated group (36.5 +/- 17.4 ng/mL) than in the control group (17.4 +/- 6.6 ng/mL; P less than .001). The unexpected increase in GH levels in the treated group could reflect either fluctuating fetal blood glucose in response to episodic betamimetic administration or direct fetal pituitary production through adrenergic stimulation.     

甲状腺自身抗体和促甲状腺素预测流产的价值

目的探讨甲状腺自身抗体和促甲状腺素（TSH）预测流产的价值。方法选择因孕前或孕早期咨询就诊的育龄妇女230例,常规筛查甲状腺自身抗体和TSH,并追访至妊娠3个月,其中42例流产（流产组）,188例持续妊娠（持续妊娠组）。比较甲状腺自身抗体和TSH引起流产的情况。结果①甲状腺自身抗体阳性患者流产率为62.5%,TSH≥2.5mIU/L的亚临床甲减患者流产率为66.7%（6/9例）,差异无统计学意义（P=0.000）;②在流产组和持续妊娠组中,甲状腺自身抗体的阳性率分别为47.6%和6.4%,TSH≥2.5mIU/L的检出率分别为14.3%和1.6%,差异均有统计学意义（P〈0.001,P=0.001）;③TSH≥2.5mIU/L伴自身抗体阳性5例,均发生流产,单纯自身抗体阳性27例,流产率为55.6%,单纯TSH≥2.5mIU/L4例,流产率为25%,TSH〈2.5mIU/L伴自身抗体阴性194例,流产率为10.8%,差异有统计学意义（P〈0.001）;④甲状腺自身抗体较TSH预测流产的价值更大,差异有统计学意义（P=0.003）。结论甲状腺自身抗体和TSH均是预测流产的重要指标,且甲状腺自身抗体的预测价值更大,两者联合可能具有更大的预测价值。     

The association of birthweight with maternal and cord serum and amniotic fluid growth hormone and insulin levels, and with neonatal and maternal factors in pregnant women who delivered at term

AIM: To investigate the influence of maternal and cord serum and amniotic fluid growth hormone (GH) and insulin and other neonatal and maternal factors on birthweight. METHODS: A total of 160 pregnant women at 38-42 weeks' gestation were studied. All infants were categorized as small for gestational age (SGA) (n = 50), large for gestational age (LGA) (n = 50) or average for gestational age (AGA) (n = 60). GH and insulin levels were measured in maternal and cord serum and amniotic fluid at birth. RESULTS: GH levels in maternal and cord serum and amniotic fluid showed no differences among the three weight groups (P > 0.05). The cord insulin level was significantly lower in SGA (P < 0.01). The insulin level in venous cord blood correlated with birth and placental weights and neonatal height, whereas maternal serum and amniotic fluid insulin levels, and maternal and cord serum and amniotic fluid GH levels did not show any correlation with birthweight. The cord GH level at birth was correlated with GH levels after 4 postnatal weeks in the SGA group (P < 0.01). In addition, birthweight showed a correlation with prepartum maternal weight, maternal weight gain, maternal height, neonatal length and placental weight in all three weight groups. CONCLUSIONS: Cord GH, maternal serum and amniotic fluid GH and insulin levels did not correlate with birthweight in all three weight groups. The lack of correlation for GH levels in maternal and cord serum and amniotic fluid suggests that these compartments may be non-communicating separate units.     

罗格列酮对多囊卵巢综合征胰岛素抵抗及高雄激素血症的治疗研究

目的　探讨胰岛素增敏剂罗格列酮对多囊卵巢综合征 (PCOS)的胰岛素抵抗及高雄激素血症的治疗效果。方法　对 30例PCOS患者给予每天早餐前口服 4mg罗格列酮 ,共 1 2周 ,比较治疗前后体重指数、胰岛素、血糖和血脂、瘦素和神经肽Y以及生殖激素水平与排卵率的变化。结果治疗 1 2周后 ,基础胰岛素水平从 (1 8± 8)mIU/L降至 (1 2± 7)mIU/L(P <0 0 1 ) ,胰岛素抵抗指数从4 3± 1 2降至 2 6± 0 7(P <0 0 1 )。黄体生成素从 (1 5 4± 4 4)U/L降至 (7 9± 2 1 )U/L ,游离睾酮从(1 2 5± 1 9)pmol/L降至 (8 9± 1 4)pmol/L ,雄烯二酮从 (9 8± 1 7)nmol/L降至 (7 4± 1 2 )nmol/L ,差异均有极显著性 (P均 <0 0 1 ) ;硫酸脱氢表雄酮从 (8 7± 3 5) μmol/L降至 (6 9± 2 1 ) μmol/L(P<0 0 5) ;性激素结合球蛋白从 (39± 3)nmol/L升至 (58± 5)nmol/L(P <0 0 1 )。血浆瘦素水平从 (1 8±4) μg/L降至 (1 3± 3) μg/L(P <0 0 1 )。 30例月经稀发的患者 ,2 5例恢复排卵 ,排卵率 50 %。 结论　罗格列酮可降低PCOS患者血浆瘦素水平 ,改善胰岛素敏感性 ,进而改善高雄激素血症等内分泌紊乱 ,恢复有排卵月经     

铜及赖氨酰氧化酶与胎膜早破的相关性研究

目的探讨孕妇血清铜(Cu)、羊膜Cu、羊膜赖氨酰氧化酶(LOX)、羊膜Ⅲ型胶原的水平之间的相关性,以及与胎膜早破的关系。方法100例胎膜早破孕妇作为胎膜早破组,其中妊娠37~42周40例、34~36周+640例、28~33周+620例;与胎膜早破组孕周、例数相对应的100例非胎膜早破孕妇作为对照组。应用火焰原子吸收法检测两组孕妇血清Cu和羊膜Cu水平,荧光发光法检测羊膜LOX水平,免疫组化法和图像分析法检测羊膜Ⅲ型胶原水平。将不同孕周孕妇血清Cu、羊膜Cu、羊膜LOX、羊膜Ⅲ型胶原测定结果进行直线相关分析,并比较胎膜早破组与对照组在这些指标上的差异。结果(1)妊娠37~42周:两组孕妇血清Cu与羊膜Cu水平呈正相关,r为0·82(P<0·001),其他各指标均无相关关系。(2)妊娠34~36周+6和28~33周+6:两组孕妇血清Cu、羊膜Cu、羊膜LOX、羊膜Ⅲ型胶原水平之间均呈正相关(P<0·01)。(3)妊娠37~42周:两组孕妇血清Cu水平与羊膜Cu比较,差异无统计学意义(P>0·05);胎膜早破组及对照组孕妇羊膜LOX水平分别为(0·53±0·10)和(0·75±0·10)μg/g(P<0·01),羊膜Ⅲ型胶原吸光度(A)值分别为0·36±0·01和0·37±0·01(P<0·05);(4)妊娠34~36周+6:胎膜早破组及对照组孕妇血清Cu水平分别为(115·23±9·56)、(139·03±10·59)mg/L,羊膜Cu水平分别为(0·19±0·04)、(0·29±0·04)μg/mg,羊膜LOX水平分别为(0·54±0·10)、(0·70±0·13)μg/g,羊膜Ⅲ型胶原A值分别为0·36±0·01、0·37±0·01。胎膜早破组以上各指标均低于对照组,两组比较,差异有统计学意义(P<0·01)。(5)妊娠28~33周+6:胎膜早破组及对照组孕妇血清Cu水平分别为(120·31±8·04)、(136·40±8·21)μg/L,羊膜Cu水平分别为(0·21±0·04)、(0·26±0·03)μg/mg,羊膜LOX水平分别为(0·62±0·09)、(0·72±0·09)μg/g,羊膜Ⅲ型胶原A值分别为0·35±0·01、0·38±0·01。胎膜早破组以上各指标均低于对照组,两组比较,差异有统计学意义(P<0·01)。结论足月妊娠的胎膜早破孕妇,其羊膜LOX和羊膜Ⅲ型胶原水平下降不受血清Cu水平的影响,这可能与羊膜的退行性变加快有关;未足月妊娠的胎膜早破孕妇血清Cu、羊膜Cu、羊膜LOX和羊膜Ⅲ型胶原的水平降低则与胎膜早破的发生直接相关。     

妊娠晚期妇女甲状腺疾病特点及甲状腺自身抗体变化的研究

目的 探讨妊娠晚期妇女甲状腺疾病的患病率、患病特点和甲状腺自身抗体的变化.方法 选择664例妊娠晚期妇女为妊娠组,276例非妊娠育龄妇女作为对照组.应用固相化学发光酶免疫法测定两组妇女的血清促甲状腺激素（TSH）和抗甲状腺过氧化物酶抗体（TPOAb）水平;TSH水平检测异常者加测游离甲状腺素（FT4）和游离三碘甲状腺原氨酸（FT3）,同时测定尿碘水平.按如下标准确定诊断：TSH＜0.3 mU/L,FT4和（或）FT3水平升高者诊断为临床甲状腺功能亢进症（甲亢）;TSH＜0.3 mU/L,而FT4和FT3水平正常者诊断为亚临床甲亢;TSH＞4.8 mU/L,FT4水平降低者诊断为临床甲状腺功能减退症（甲减）;TSH＞4.8 mU/L,而FT4和FT3水平正常者诊断为亚临床甲减.TPOAb＞5 kU/L为阳性.结果 （1）妊娠组妇女尿碘平均水平为201.5μg/L,对照组妇女尿碘平均水平为196.0μg/L,均为碘充足水平.两组比较,差异无统计学意义（P＞0.05）.（2）妊娠组妇女甲状腺疾病总患病率为7.8%（52/664）,对照组妇女甲状腺疾病总患病率为6.9%（19/276）.两组比较,差异无统计学意义（P＞0.05）.（3）两组妇女的甲状腺患病类型有明显不同,妊娠组妇女甲亢患病率为1.1%（7/664）,甲减患病率为6.8%（45/664）,妊娠组妇女甲亢患病率明显低于甲减,两者比较,差异有统计学意义（P＜0.01）;对照组甲亢患病率为4.7%（13/276）,甲减患病率为2.2%（6/276）,两者比较,差异无统计学意义（P＞0.05）.妊娠组与对照组妇女的甲亢或甲减患病率分别比较,差异均有统计学意义（P＜0.01）.（4）妊娠组非患病妇女的TSH水平显著高于对照组,分别为2.50 mU/L及1.54 mU/L,差异有统计学意义（P＜0.01）;妊娠组妇女TPOAb阳性率显著低于对照组,分别为3.3%（22/664）及9.4%（26/276）,差异有统计学意义（P＜0.01）.结论 妊娠晚期妇女甲状腺疾病的特点是甲减的患病率高,同时甲状腺自身免疫功能受到抑制.     

Glucose, insulin, HGH and IGF-I levels in maternal serum, amniotic fluid and umbilical venous serum: a comparison between late normal pregnancy and pregnancies complicated with diabetes and fetal growth retardation.

Fetal growth and development is dependent upon various growth factors such as glucose, insulin, HGH and IGF-I. These growth factors were measured in maternal serum (MS), amniotic fluid (AF) and umbilical venous serum (UV) in late gestation in normal, insulin dependent diabetic pregnancies (IDDM) and in pregnancies complicated with intrauterine growth retardation (IUGR). The UV glucose values of 1.9 +/- 0.9 mmol/L and UV insulin values of 8.0 +/- 1.8 mU/L were the lowest in IUGR pregnancies, and the highest were in UV serum from IDDM pregnancies, and the difference was statistically significant for this two groups. IGF-I values in UV indicated that there was significant difference in IGF-I concentrations when both, IUGR and IDDM groups were compared to the controls. There was a parallel shift in AF and MS glucose and insulin concentration as birthweight increased. The highest IGF-I values of 7.2 +/- 9.6 mumol/L in AF and MS were found in pregnancies with infants whose birthweight was 3500 grams and greater. Infants from pregnancies complicated with IUGR and IGF-I low values of 0.6 +/- 1.2 mumol/L in AF. HGH concentrations of 15.6 +/- 9.4 micrograms/L in UV were observed in IDDM pregnancies and significantly lower than the values in IUGR and normal pregnancies. HGH umbilical venous values decreased with duration of pregnancy and with increase in fetal size. The high HGH concentrations in the fetus and its dramatic fall after parturition, and the obtained negative correlation between HGH and IGF-I in umbilical vein may exhibit the maturation of the hypothalamic-growth hormone-IGF-I axis. It seems likely that changes in maternal serum, umbilical venous and amniotic fluid insulin-like growth factor I influence birthweight in normal and IUGR infants and in those of diabetic mothers.     

Metabolic and cardiovascular changes in women with polycystic ovary syndrome.

OBJECTIVE: To analyze the relationship between QTc interval and cardiovascular risk factors in women with polycystic ovary syndrome (PCOS). METHODS: Study group included 119 PCOS women (age: 32.2+/-5.2 years) and the control group 64 age-matched healthy women; they all underwent QT interval measurement, and plasma levels of high-sensitivity CRP (hsCRP), endothelin-1 (ET1), insulin, and testosterone determinations. RESULTS: In PCOS women hsCRP (2.35+/-2.14 mg/L vs. 1.01+/-1.28 mg/L; P=0.04), ET1 (23.6+/-10.3 ng/L vs. 7.7+/-15.9 ng/L; P=0.01), and insulin (16.5+/-7.8 mIU/L vs. 11.8+/-10.7 mIU/L; P=0.03) levels were significantly higher, and QTc interval significantly shorter than in controls (401+/-61 ms vs. 467+/-61 ms; P=0.007). In 67 (56%) PCOS patients with a short QTc interval (<400 ms), plasma testosterone levels were significantly higher than in PCOS women with normal QTc interval (2.3+/-2.1 nmol/L vs. 1.4+/-1.7 nmol/L; P=0.02). CONCLUSIONS: In patients with polycystic ovary syndrome increased testosterone levels may attenuate the effects of coronary risk factors.